p53 (polyubiquitinated) (human) (rec.) (His)

CHF 639.00
In stock
SBB-US0012-C02020 µgCHF 639.00
More Information
Product Details
Synonyms Cellular Tumor Antigen p53; Tumor Suppressor p53; TP53
Product Type Protein
Source/Host E. coli
Sequence Human p53 (aa 2-393) (Accession Nr. P04637) fused to a N-terminal His-tag, ubiquitinated by MDM2, and subsequently purified from conjugation-reaction proteins/enriched post-conjugation.
Crossreactivity Human
Application Typical working concentrations range is 0.5-2µM.
MW >40kDa. Western blot analysis shows multiple states of poly-ubiquitination, and deconjugation with USP7 shows purified ubiquitinated p53 can function as a native substrate.
Purity ≥95% (SDS-PAGE)
Concentration Lot dependent.
Accession Number P04637
Formulation Liquid. In 50mM HEPES pH 7.5, 500 mM sodium chloride, 10% glycerol, 2mM TCEP.
Other Product Data Click here for a Typical Lot-specific Product Datasheet from the Original Manufacturer
Our product description may differ slightly from the original manufacturers product datasheet.
Declaration Manufactured by South Bay Bio.
Shipping and Handling
Shipping DRY ICE
Short Term Storage -80°C
Long Term Storage -80°C
Handling Advice Aliquot to avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -80°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

p53 acts as a tumor suppressor in many tumor types, induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. E3 ligase MDM2 mediated ubiquitin conjugation of p53 and subsequent p53 down-regulation via proteasomal degradation interrupts this crucial role, contributing to tumorogenesis (and cancer).

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.